Stanford University Cancer Institute (Palo Alto)

Sorting 1 by

Accepting patients

BMS-986453

A Phase 1, Open-Label, Dose-Finding Study of BMS-986453, Dual Targeting BCMAxGPRC5D Chimeric Antigen Receptor T Cells, in Participants With Relapsed and/or Refractory Multiple Myeloma
Learn more
  • CAR T Cell
  • BCMA
  • GPRC5D
  • Phase 1
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials